Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces results of biomarker analysis

Amgen announces results of biomarker analysis

26th September 2007

Amgen has announced the results of a biomarker analysis that links the KRAS gene to the clinical response of Vectibix – indicated for the treatment of patients with epidermal growth factor receptor (EGFR).

The phase III clinical trial supports KRAS as a predictive clinical biomarker that could be used to select patients who are more likely to respond to treatment with Vectibix (panitumumab) monotherapy.

Primary and secondary endpoints were met by showing that Vectibix exclusively targeted around 60 per cent of patients whose tumors contained normal, non-mutated (wild-type) KRAS.

Tim Turnham, chief executive officer of Colon Cancer Alliance described the biomarker analysis as an “important step forward” in the improvement of personalised cancer care.

“Being able to select which patients may benefit from treatment would reduce the individual patient and societal burdens often associated with cancer therapy,” he said.

Data was generated from an analysis of the treatment effect of Vectibix in patients with metastatic colorectal cancer (mCRC).

Earlier this week, Amgen announced that it had received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation of Vectibix (panitumumab) in the European Union.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.